Literature DB >> 7784022

Carcinoma of the vulva in young women.

M J Messing1, D G Gallup.   

Abstract

OBJECTIVE: To determine if young women with carcinoma of the vulva have a different risk factor history and outcome compared with older women.
METHODS: We conducted a retrospective review of the medical records of 78 women treated at the Medical College of Georgia for squamous carcinoma of the vulva during 1979-1993. Women younger than 45 years were compared with those 45 and over for historic risk factors, treatment modality, and outcome.
RESULTS: Over the study interval, the average presenting age of these patients decreased from 69 to 55 years. Women under 45 were found to have a stronger history of condyloma (P < .001, 95% confidence interval [CI] 3.69-87.96). There was no significant difference by age in the duration of symptoms before presentation, smoking history, or tumor size. Women 45 and over were more likely to have advanced-stage disease (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV) (P = .03, 95% CI 0.43-0.91). Treatment did not differ significantly with age. In a univariate analysis, advanced FIGO stage, presence of metastases, and tumor size were associated with shorter survival. There was no detected difference in survival for women in either age group.
CONCLUSION: There appears to be a trend in our patient population toward younger women presenting with squamous carcinoma of the vulva. Human papillomavirus infection appears to be more common in younger women with vulvar carcinoma. There may be a difference in the etiologies producing squamous carcinomas of the vulva. Education encouraging the early detection and prevention of sexually transmitted diseases might alter the rising incidence of this disease in younger women.

Entities:  

Mesh:

Year:  1995        PMID: 7784022     DOI: 10.1016/0029-7844(95)00101-V

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  11 in total

1.  Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.

Authors:  Krystle A Lang Kuhs; Paula Gonzalez; Ana Cecilia Rodriguez; Leen-Jan van Doorn; Mark Schiffman; Linda Struijk; Sabrina Chen; Wim Quint; Douglas R Lowy; Carolina Porras; Corey DelVecchio; Silvia Jimenez; Mahboobeh Safaeian; John T Schiller; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Aimée R Kreimer
Journal:  J Infect Dis       Date:  2014-06-23       Impact factor: 5.226

2.  An unusual presentation of vulvar carcinoma: a traumatic aetiology?

Authors:  J M Weinberg; J Chung; I A Tangoren; R I Rudolph
Journal:  Genitourin Med       Date:  1997-04

3.  Management of patients with vulvar cancer: a perspective review according to tumour stage.

Authors:  Linn Woelber; Fabian Trillsch; Lilli Kock; Donata Grimm; Cordula Petersen; Matthias Choschzick; Fritz Jaenicke; Sven Mahner
Journal:  Ther Adv Med Oncol       Date:  2013-05       Impact factor: 8.168

4.  Cell cycle suppressor proteins are not related to HPV status or clinical outcome in patients with vulvar carcinoma.

Authors:  André Mourão Lavorato-Rocha; Iara Sant'ana Rodrigues; Beatriz de Melo Maia; Mônica Maria Ágata Stiepcich; Glauco Baiocchi; Kátia Cândido Carvalho; Fernando Augusto Soares; José Vassallo; Rafael Malagoli Rocha
Journal:  Tumour Biol       Date:  2013-07-06

5.  Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.

Authors:  Zhihui Wang; Claes G Trope; Vivi Ann Flørenes; Zhenhe Suo; Jahn M Nesland; Ruth Holm
Journal:  BMC Cancer       Date:  2010-05-25       Impact factor: 4.430

6.  The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3β and ε are independent prognostic factors for these tumors.

Authors:  Zhihui Wang; Jahn M Nesland; Zhenhe Suo; Claes G Trope; Ruth Holm
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

7.  Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Ruth Holm; Mette Førsund; Mai T Nguyen; Jahn M Nesland; Claes G Trope
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

8.  The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas.

Authors:  Zhihui Wang; Claes G Tropè; Zhenhe Suo; Gunhild Trøen; Guanrui Yang; Jahn M Nesland; Ruth Holm
Journal:  BMC Cancer       Date:  2008-10-24       Impact factor: 4.430

9.  Primary tumor vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact.

Authors:  Hari Prasad Dhakal; Jahn M Nesland; Mette Førsund; Claes G Trope; Ruth Holm
Journal:  BMC Cancer       Date:  2013-10-29       Impact factor: 4.430

10.  A Very Rare Case: HPV-Negative Vulvar Cancer in an Adolescent.

Authors:  Ilker Kahramanoglu; Hasan Turan; Yahya Ozgun Oner; Tugan Bese; Sennur Ilvan; Macit Arvas; Fuat Demirkiran
Journal:  Case Rep Obstet Gynecol       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.